Targeted therapies in neuroendocrine neoplasms
Journal Title: OncoReview - Year 2012, Vol 2, Issue 3
Abstract
The primary treatment of gastrointestinal neuroendocrine tumors is surgery, and its extent depends on the clinical stage of cancer. In advanced disease medical therapy is used. One possible form of treatment is biological therapy and radionuclide therapy (PRRT, peptide receptor radionuclide therapy) using radiolabeled somatostatin analogues. The effects of these treatments can improve the combinations of radioactive labeled somatostatin analogues, intra-arterial administered, and the use of radio sensitizing drugs combined with PRRT or PRRT combined with new targeted therapeutic agents such as sunitinib or everolimus. New targeted agents (angiogenesis inhibitors, single and multiple tyrosine kinase inhibitors and new somatostatin analogues, such as pasyreotyd) also evaluated in II and III phase clinical trials. Currently, there are several studies on the efficacy of a combination of different, present and new treatments. PRRT with the combination of sunitinib or everolimus or sequential use of PRRT and one of these compounds may be a promising solution for the treatment of patients with pancreatic endocrine tumors.
Authors and Affiliations
Violetta Rosiek, Beata Kos-Kudła
Keywords
Related Articles
- EP ID EP53164
- DOI -
- Views 265
- Downloads 0
Perioperative treatment of oesophageal, oesophago-gastric adenocarcinoma: new standards of care and controversies
Oesophageal, gastroesophageal and gastric cancers represent important diagnostic and therapeutic challenge. Even after radical surgical procedure (R0) 5-year survival remains unsatisfactory. It is assumed that perioperat...
Original vs generic drugs in treatment of chronic myeloid leukaemia
The beginning of the twenty-first century saw a breakthrough in haematology, oncology and general medicine driven by the introduction of imatinib (Glivec) to the treatment of chronic myeloid leukaemia. For the first time...
Superior efficacy of nilotinib vs imatinib in patients with chronic myeloid leukemia in chronic phase. ENESTnd and ENESTcmr current results analysis
Second generation tyrosine kinase inhibitors can improve the efficacy of treatment and outcome in newly diagnosed patients with chronic myeloid leukemia in chronic phase. The primary endpoint of ENESTnd trial is the comp...
Meeting the human. What can I get out of it?
Recently patients representatives are more often invited to oncological congresses. They would like to draw attention of the medical society to other than medical problems of people with cancer. Doctors should remember h...
Nowe możliwości celowanego leczenia uogólnionego raka piersi z ekspresją receptorów hormonalnych
Badania molekularne wykazały, że rak piersi jest grupą heterogennych chorób o różnych cechach biologicznych i różnym rokowaniu. Z klinicznego punktu widzenia raka piersi podzielić można na trzy różne typy o odmiennej pod...